Quanterix’s Simoa® Revolutionize Your Neurological Diagnostics with CLIA-Validated NfL Laboratory Developed Tests

Neurofilament light chain (NfL) has become an invaluable biomarker for the early detection and monitoring of various neurological diseases. NfL levels rise above baseline when neuronal injury or degeneration occurs, offering a unique biomarker to assess associated damage with high accuracy.

Learn more

Partner With Us in Advancing Neurology Diagnostics

We’d love to hear your ideas for innovative studies and work together on making a difference clinically and scientifically.

    Multiple Sclerosis

    Numerous studies have been conducted to assess the role of NfL in assessing disease progression, treatment efficacy and patient outcomes. These findings can be leveraged for improved healthcare management strategies.1-15

    Alzheimer’s Disease

    NfL levels have been found to rise in patients displaying symptoms of cognitive decline, effectively identifying the progression and severity of their disease. This discovery has major implications for early diagnosis and treatment.16-19

    Parkinson’s Disease

    Parkinson’s Disease patients experience heightened difficulties with motor and cognitive abilities, which has been linked to increasing levels of NfL biomarkers. This research highlights the crucial role of monitoring these markers in understanding disease progression.20-22

    Traumatic Brain Injury

    Recent research has revealed an undeniable connection between Traumatic Brain Injury and elevated NfL levels. This provides clinicians with invaluable insight into detecting neurodegenerative changes in patients as well as evaluating the success of therapeutic interventions.23-27

    Amyotrophic Lateral Sclerosis (ALS)

    Elevated NfL levels can serve as a powerful predictor of disease progression in patients. By providing accurate and precise measurement of NfL levels in ALS patients, researchers are driving forward our understanding of this complex and devastating disease.28-33

    Huntington’s Disease

    Groundbreaking work in measuring NfL levels in Huntington’s Disease patients has opened up new avenues for early diagnosis and intervention, offering hope to those affected by this devastating condition.34-36

    Frontotemporal Dementia (FTD)

    Revolutionary research has unveiled a groundbreaking biomarker, NfL levels, which can serve as an early and accurate predictor of disease progression in FTD patients. Advanced technology is providing clinicians with more reliable insights into FTD diagnosis – paving the way for better outcomes and improved patient care.


    Breakthrough research has uncovered a reliable, predictive biomarker for stroke patients. This pioneering technology is shifting the paradigm of disease management by equipping clinicians with an unprecedented level of diagnostic accuracy and helping to improve patient outcomes on a global scale.

    The Benchmark for Neurofilament Testing

    Fully Automated Digital Immunoassay for Neurofilament Light Chain in Blood

    Download whitepaper


    View details on our LDT for the quantitative determination of neurofilament light in blood

    Learn more

    Publication in Review

    Serum neurofilament light chain reference database for individual application in paediatric care

    See more Simoa® NfL publications

    Upcoming Publication

    Development and Multi-Center Validation of a Fully Automated Digital Immunoassay for Neurofilament Light Chain: Toward a Clinical Blood Test for Neuronal Injury

    View additional neurology publications

    Related Studies

    1. Akgün K, Kretschmann N, Haase R, et al. Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. Neurol Neuroimmunol NeuroiNf-Lamm. 2019 Apr 8;6(3):e555.
    2. Serum neurofilament light (Nf-L) for disease prognosis and treatment monitoring in multiple sclerosis patients: is it ready for implementation into clinical care? ECTRIMS Online Library. Calabresi P. 10/11/18; 231907; 158 https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/231907/peter.calabresi.serum.neurofilament.light.%28Nf-L%29.for.disease.prognosis.and.html3.
    3. Calabresi P, Kuhle J, Arnold D, et al. Serum neurofilament light (Nf-L) for disease prognosis and treatment monitoring in multiple sclerosis patients: toward implementation in clinical care. Neurology. April 09, 2019; 92 (15 Supplement) MAY 7, 20195. Serum neurofilament light levels at the time of a clinically isolated syndrome are associated with long-term clinical and radiological outcome ECTRIMS Online Library. Plavina T. 10/26/17; 200284; P629  https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/200284/tatiana.plavina.serum.neurofilament.light.levels.at.the.time.of.a.clinically.html
    4. Thebault S, Booth RA, Rush CA, MacLean H, Freedman MS. Serum neurofilament light chain measurement in MS: hurdles to clinical translation. Front Neurosci. 2021 Mar 25;15:654942.7.
    5. Disanto G, Barro C, Benkert P, et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017 Jun;81(6):857-870.8.
    6. Bittner S, Oh J, Havrdová EK, Tintoré M, Zipp F. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain. 2021 Nov 29;144(10):2954-2963.
    7. Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019 Mar 5;92(10):e1007-e1015.
    8. Novakova L, Zetterberg H, Sundström P, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017 Nov 28;89(22):2230-2237.
    9. Valentino P, Marnetto F, Martire S, et al. Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice. Mult Scler Relat Disord. 2021 Sep;54:103090.
    10. Szilasiová J, Mikula P, Rosenberger J, et al. Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss. Mult Scler. 2021 Nov;27(13):2023-2030.
    11. Kuhle J, Nourbakhsh B, Grant D, et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology. 2017;88(9):826-831.
    12. Siller N, Kuhle J, Muthuraman M, et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler. 2019;25(5):678-686.
    13. Thebault S, Abdoli M, Fereshtehnejad SM, Terssier D, Tabard-Cossa V, Freedman MS. Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci Rep. 2020 Jun 25;10(1):10381.
    14. Calabresi PA, Arnold DL, Sangurdekar D, et al. Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring. Mult Scler. 2021 Sep;27(10):1497-1505.
    15. Harris S, Comi G, Cree BAC, et al. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. Eur J Neurol. 2021 Nov;28(11):3722-3730.
    16. Lee EH, Kwon HS, Koh SH, et al. Serum neurofilament light chain level as a predictor of cognitive stage transition. Alzheimers Res Ther. 2022;14(1):6. Published 2022 Jan 7.
    17. Sugarman MA, Zetterberg H, Blennow K, et al. A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer’s disease. Neurobiol Aging. 2020 Oct;94:60-70.
    18. Moscoso A, Grothe MJ, Ashton NJ, et al. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain with Neurodegeneration in Alzheimer Disease. JAMA Neurol. 2021 Apr 1;78(4):396-406.
    19. Lewczuk P, Ermann N, Andreasson U, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimers Res Ther. 2018;10(1):71. Published 2018 Jul 28.
    20. Lin CH, Li CH, Yang KC et al. Blood Nf-L: A biomarker for disease severity and progression in Parkinson disease. Neurology. 2019;93(11):e1104-e111
    21. Zhu Y, Yang B, Wang F, et al. Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson’s disease. J Neuroimmunol. 2021;358:577662.
    22. Sampedro F, Pérez-González R, Martínez-Horta S, Marín-Lahoz J, Pagonabarraga J, Kulisevsky J. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson’s disease. Parkinsonism Relat Disord. 2020;74:43-49.
    23. Shahim P, Politis A, van der Merwe A, et al. Neurofilament light as a biomarker in traumatic brain injury [published correction appears in Neurology. 2021 Mar 23;96(12):593]. Neurology. 2020;95(6):e610-e622.
    24. Shahim P, Tegner Y, Marklund N, et.al. Neurofilament light and tau as blood biomarkers for sports-related concussion. Neurology. 2018; 90:e1780-e1788.
    25. McDonald SJ, O’Brien WT, Symons GF, et.al. Prolonged elevation of serum neurofilament light after concussion in male Australian football players. Biomarker Research. 2021. 9:4.
    26. Karantali E, Kazis D, McKenna J, et.al. Neurofilament light chain in patients with a concussion or head impacts: asystematic review and meta-analysis. European Journal of Trauma and Emergency Surgery. 2021, 8 May.
    27. Shahim, P., Gren, M., Liman, V. et al. Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep 6, 36791 (2016).
    28. Benatar M, Wuu J, Lombardi V, et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7-8):538-548.
    29. Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015 Jun 2;84(22):2247-2257.
    30. Thouvenot E, Demattei C, Lehmann S, et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. 2020 Feb;27(2):251-257.
    31. https://www.clinicaltrialsarena.com/news/news-adcom-als-accelerated-approval-tofersen/
    32. https://biogen.gcs-web.com/static-files/b2154d4e-f69f-49d4-9a61-e834387293ea
    33. Brousse M, Delaby C, De La Cruz E, et al. Serum neurofilament light chain cut-off definition for clinical diagnosis and prognosis of amyotrophic lateral sclerosis [published online ahead of print, 2023 Apr 8]. Eur J Neurol. 2023;10.1111/ene.15813.
    34. Byrne LM, Rodrigues FB, Blennow K, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. Lancet Neurol. 2017 Aug;16(8):601-609.
    35. Scahill RI, Zeun P, Osborne-Crowley K et al. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurol. 2020;19(6):502-512.
    36. Byrne, L.M., Schultz, J.L., Rodrigues, F.B., van der Plas, E., Langbehn, D., Nopoulos, P.C. and Wild, E.J. (2022), Neurofilament light protein as a potential blood biomarker for huntington’s disease in children. Mov Disord, 37: 1526-1531.